nach oben

Erschienen in:

01.01.2012 | Original paper

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening

verfasst von: Anne Kricker, Tracey DiSipio, Jennifer Stone, Chris Goumas, Jane E. Armes, Dorota M. Gertig, Bruce K. Armstrong

Erschienen in: Cancer Causes & Control | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the factors associated with symptom-detected breast cancers in a population offered screening.

Methods

We interviewed 1,459 Australian women aged 40–69, 946 with symptom-detected and 513 with mammogram-detected invasive breast cancers ≥1.1 cm in diameter about their personal, mammogram, and breast histories before diagnosis and reviewed medical records for tumor characteristics and mammogram dates, calculating ORs and 95% confidence intervals (CIs) for symptom- versus mammogram-detected cancers in logistic regression models.

Results

Lack of regular mammograms (<2 mammograms in the 4.5 years before diagnosis) was the strongest correlate of symptom-detected breast cancer (OR = 3.04 for irregular or no mammograms). In women who had regular mammograms (≥2 mammograms in the 4.5 years before diagnosis), the independent correlates of symptom-detected cancers were low BMI (OR < 25 kg/m² vs. ≥ 30 kg/m² = 2.18, 95% CI 1.23–3.84; p = 0.008), increased breast density (available in 498 women) (OR highest quarter vs. lowest = 3.50, 95% CI 1.76–6.97; p _trend = 0.004), high-grade cancer, and a larger cancer (each p < 0.01). In women who did not have regular mammograms, the independent correlates were age <50 years, a first cancer, and a ≥2-cm cancer. Smoking appeared to modify the association of symptom-detected cancer with low BMI (higher ORs for low BMI in current smokers) and estrogen receptor (ER) status (higher ORs for low BMI in ER cancers).

Conclusion

Women with low BMI may benefit from a tailored approach to breast cancer detection, particularly if they smoke.

Newcomer LM, Newcomb PA, Trentham-Dietz A et al (2002) Detection method and breast carcinoma histology. Cancer 95(3):470–477PubMedCrossRef

Cheung S, Greenway N, Lagord C, Williams L, Kearns O, Lawrence G (2009) All breast cancers report. A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006. National Cancer Intelligence Network, NHS Cancer Screening Programmes

International Agency for Research on Cancer (2002) Breast cancer screening. International Agency for Research on Cancer, Lyon

Australian Institute of Health and Welfare (AIHW) (2006) Breast screen Australia monitoring report 2002–2003. AIHW (Cancer Series no. 32), Canberra

Taylor R, Supramaniam R, Rickard M, Estoesta J, Moreira C (2002) Interval breast cancers in New South Wales, Australia, and comparisons with trials and other mammographic screening programmes. J Med Screen 9(1):20–25PubMedCrossRef

Bennett RL, Sellars SJ, Moss SM (2011) Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. Br J Cancer 104(4):571–577PubMedCrossRef

Australian Institute of Health and Welfare, National Breast Cancer Centre (2001) Breast cancer size and nodal status. AIHW, Canberra

Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028PubMedCrossRef

Kricker A, Newman B, Gertig DM, Goumas C, Armes J, Armstrong BK (2008) Why do large breast cancers still present in a population offered screening? Int J Cancer 123:2907–2914PubMedCrossRef

10.

Byng JW, Yaffe MJ, Jong RA et al (1998) Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18(6):1587–1598PubMed

11.

Simpson JA, English DR, MacInnis RJ, Gertig DM, Hopper JL, Giles GG (2007) A comparison of different methods for including ‘age at menopause’ in analyses of the association between hormone replacement therapy use and breast cancer. J Fam Plann Reprod Health Care 33(1):11–16PubMedCrossRef

12.

WHO expert committee on physical status (1995) Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. World Health Organisation, Geneva

13.

Yasui Y, Potter JD (1999) The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10(5):431–437PubMedCrossRef

14.

Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219PubMedCrossRef

15.

Australian Institute of Health and Welfare (AIHW) (2007) Breast screen Australia monitoring report 2003–2004. AIHW (Cancer Series no. 36), Canberra

16.

Bihrmann K, Jensen A, Olsen AH et al (2008) Performance of systematic and non-systematic (‘opportunistic’) screening mammography: a comparative study from Denmark. J Med Screen 15(1):23–26PubMedCrossRef

17.

Elmore JG, Carney PA, Abraham LA et al (2004) The association between obesity and screening mammography accuracy. Arch Intern Med 164(10):1140–1147PubMedCrossRef

18.

Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS (2008) Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst 100(23):1724–1733PubMedCrossRef

19.

Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC (1995) Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 142(8):813–819PubMed

20.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V (1996) Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276(1):33–38PubMedCrossRef

21.

Banks E, Reeves G, Beral V et al (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477PubMedCrossRef

22.

Deglise C, Bouchardy C, Burri M et al (2010) Impact of obesity on diagnosis and treatment of breast cancer. Breast Cancer Res Treat 120(1):185–193PubMedCrossRef

23.

de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C (1984) The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis 37(1):1–44PubMedCrossRef

24.

Brekelmans CT, Peeters PH, Faber JA, Deurenberg JJ, Collette HJ (1994) The epidemiological profile of women with an interval cancer in the DOM screening programme. Breast Cancer Res Treat 30(3):223–232PubMedCrossRef

25.

Mandelson MT, Oestreicher N, Porter PL et al (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92(13):1081–1087PubMedCrossRef

26.

De Stavola BL, Gravelle IH, Wang DY et al (1990) Relationship of mammographic parenchymal patterns with breast cancer risk factors and risk of breast cancer in a prospective study. Int J Epidemiol 19(2):247–254PubMedCrossRef

27.

Sala E, Warren R, McCann J, Duffy S, Luben R, Day N (2000) High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. Int J Epidemiol 29(4):629–636PubMedCrossRef

28.

Boyd NF, Martin LJ, Sun L et al (2006) Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15(11):2086–2092PubMedCrossRef

29.

Sung J, Song YM, Stone J, Lee K, Kim SY (2010) Association of body size measurements and mammographic density in Korean women: the healthy twin study. Cancer Epidemiol Biomarkers Prev 19(6):1523–1531PubMedCrossRef

30.

Willett WC, Browne ML, Bain C et al (1985) Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 122(5):731–740PubMed

31.

Hankinson SE, Willett WC, Manson JE et al (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87(17):1297–1302PubMedCrossRef

32.

Cunningham JE, Butler WM (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88(2):161–176PubMedCrossRef

33.

Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92(1):37–45PubMedCrossRef

34.

Shen Y, Costantino JP, Qin J (2008) Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 100(20):1448–1453PubMedCrossRef

35.

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11(7):653–662PubMedCrossRef

36.

Butler LM, Gold EB, Conroy SM et al (2010) Active, but not passive cigarette smoking was inversely associated with mammographic density. Cancer Causes Control 21(2):301–311PubMedCrossRef

37.

Bremnes Y, Ursin G, Bjurstam N, Gram IT (2007) Different measures of smoking exposure and mammographic density in postmenopausal Norwegian women: a cross-sectional study. Breast Cancer Res 9(5):R73PubMedCrossRef

38.

Brand JS, Chan MF, Dowsett M, et al. (2011) Cigarette Smoking and Endogenous Sex Hormones in Postmenopausal Women. J Clin Endocrinol Metab. doi:10.1210/jc.2011-1165

39.

Pasquali R, Vicennati V, Bertazzo D et al (1997) Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 46(1):5–9PubMedCrossRef

40.

Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175PubMed

41.

Kavanagh AM, Byrnes GB, Nickson C et al (2008) Using mammographic density to improve breast cancer screening outcomes. Cancer Epidemiol Biomarkers Prev 17(10):2818–2824PubMedCrossRef

42.

Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E (2009) Breast density and outcome of mammography screening: a cohort study. Br J Cancer 100(7):1205–1208PubMedCrossRef

43.

Aiello EJ, Buist DS, White E, Porter PL (2005) Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev 14(3):662–668PubMedCrossRef

44.

Ghosh K, Brandt KR, Sellers TA et al (2008) Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(4):872–879PubMedCrossRef

45.

Australian Institute of Health and Welfare (AIHW) (2005) Breast screen Australia monitoring report 2001–2002. AIHW (Cancer Series no. 29), Canberra

46.

Joensuu H, Lehtimaki T, Holli K et al (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292(9):1064–1073PubMedCrossRef

47.

Sihto H, Lundin J, Lehtimaki T et al (2008) Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14(13):4103–4110PubMedCrossRef

48.

Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105–110PubMedCrossRef

49.

Schousboe JT, Kerlikowske K, Loh A, Cummings SR (2011) Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med 155(1):10–20PubMed

50.

Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009) Screening for breast cancer: an update for the US preventive services task force. Ann Intern Med 151(10):727–742PubMed

51.

Kerlikowske K (2009) Evidence-based breast cancer prevention: the importance of individual risk. Ann Intern Med 151(10):750–752PubMed

Titel: Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening
verfasst von: Anne Kricker
Tracey DiSipio
Jennifer Stone
Chris Goumas
Jane E. Armes
Dorota M. Gertig
Bruce K. Armstrong
Publikationsdatum: 01.01.2012
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9858-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening